<DOC>
	<DOCNO>NCT02184884</DOCNO>
	<brief_summary>The whole blood Thrombelastograph ( TEG® ) Platelet Mapping™ assay measure clot strength , maximal amplitude ( MA ) , reflect maximal platelet function , detect reduction platelet function , present percentage inhibition , aspirin clopidogrel . A study report TEG® use routine monitoring variability ADP receptor inhibition antiplatelet therapy . Therefore , use TEG Platelet Mapping assay , could find perioperative clopidogrel responsiveness patient ACS undergo OPCAB . The purpose study determine whether rate major adverse cardiac event ( MACE , combine endpoint MI , revascularization cardiac death ) high patient high degree clopidogrel resistance , schedule undergo OPCAB due ACS .</brief_summary>
	<brief_title>Effect Perioperative Clopidogrel Responsiveness Ischemic Outcome Patients With Acute Coronary Syndrome Undergoing Off-pump Coronary Artery Bypass Surgery</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>1. patient ACS undergo OPCAB 2. patient administrate aspirin 100 mg clopidogrel 75 mg least 7 day continue within 3days surgery . 1. reoperation emergency operation 2. patient bleed tendency decrease liver function 3 . Left ventricular ejection fraction &lt; 40 % echo 4. preoperative hematocrit &lt; 33 % platelet count &lt; 100,000/mm3 creatinine &gt; 1.4 mg/dL 5. abnormal preoperative prothrombin time activate partial thromboplastin time 6. preoperative use PO antiplatelet drug PO anticoagulant</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>off-pump coronary artery bypass surgery , clopidogrel responsiveness , ischemic outcome</keyword>
</DOC>